JP2018064568A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018064568A5 JP2018064568A5 JP2017223489A JP2017223489A JP2018064568A5 JP 2018064568 A5 JP2018064568 A5 JP 2018064568A5 JP 2017223489 A JP2017223489 A JP 2017223489A JP 2017223489 A JP2017223489 A JP 2017223489A JP 2018064568 A5 JP2018064568 A5 JP 2018064568A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- truncated
- nucleic acid
- composition according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100019764 PDCD1 Human genes 0.000 claims 13
- 108060007796 SPATA2 Proteins 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 210000004027 cells Anatomy 0.000 claims 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 230000000139 costimulatory Effects 0.000 claims 2
- 230000003834 intracellular Effects 0.000 claims 2
- 102100005826 CD19 Human genes 0.000 claims 1
- 101700087100 CD19 Proteins 0.000 claims 1
- 102100019461 CD28 Human genes 0.000 claims 1
- 101700033362 CD28 Proteins 0.000 claims 1
- 238000003782 apoptosis assay Methods 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000005522 programmed cell death Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
Claims (11)
- ヒトＴ細胞を含む医薬組成物であって、
前記ヒトＴ細胞は：
機能的ＰＤ−１細胞内ドメインを欠き、且つヒトＴ細胞におけるプログラム細胞死リガンド１（ＰＤ−Ｌ１）の阻害効果を減少させる切断型プログラム細胞死タンパク質１（ＰＤ−１）をコードする第１核酸；及び
標的細胞の腫瘍抗原を認識する細胞外ドメイン、膜貫通ドメイン、並びにＣＤ３−ゼータシグナルドメイン及び共刺激分子のシグナルドメインを含む細胞内ドメインを含むキメラ抗原受容体（ＣＡＲ）をコードする第２核酸；
を含み、
前記切断型ＰＤ−１及び前記ＣＡＲが別個のポリペプチドである遺伝子産物として発現される、医薬組成物。 - 前記切断型ＰＤ−１は、ヒト細胞のヒトＴ細胞のＰＤ−１と、特定の細胞のＰＤ−Ｌ１との間の経路に干渉する、請求項１に記載の医薬組成物。
- 前記切断型ＰＤ−１は、ＰＤ−１細胞外ドメイン若しくはＰＤ−１膜貫通ドメイン又はそれらの組み合わせを含む、請求項１又は２に記載の医薬組成物。
- 前記切断型ＰＤ−１は、配列番号９のアミノ酸配列若しくは配列番号１０のアミノ酸配列又はそれらの組み合わせを含む、請求項１〜３のいずれか１項に記載の医薬組成物。
- 前記切断型ＰＤ−１は、特定の細胞のＰＤ−Ｌ１と結合するＰＤ−１細胞外ドメインを含む可溶性受容体である、請求項１〜４のいずれか１項に記載の医薬組成物。
- 前記腫瘍抗原がＣＤ１９である、請求項１〜５のいずれか１項に記載の医薬組成物。
- 前記共刺激分子は、４−１ＢＢ若しくはＣＤ２８又はそれらの組み合わせを含む、請求項１〜６のいずれか１項に記載の医薬組成物。
- 前記切断型ＰＤ−１は、配列番号１２のアミノ酸配列、配列番号１３のアミノ酸配列、又は配列番号１４のアミノ酸配列を含む、請求項１〜７のいずれか１項に記載の医薬組成物。
- 請求項１〜７のいずれか１項に記載の第１核酸及び第２核酸を含む、単離核酸。
- 請求項９に記載の前記単離核酸を含む、ベクター。
- 請求項９に記載の前記単離核酸を含む、細胞。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562126804P | 2015-03-02 | 2015-03-02 | |
| US62/126,804 | 2015-03-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546893A Division JP6336684B2 (ja) | 2015-03-02 | 2016-03-01 | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018064568A JP2018064568A (ja) | 2018-04-26 |
| JP2018064568A5 true JP2018064568A5 (ja) | 2019-02-21 |
| JP6767347B2 JP6767347B2 (ja) | 2020-10-14 |
Family
ID=56848306
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546893A Active JP6336684B2 (ja) | 2015-03-02 | 2016-03-01 | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
| JP2017223489A Active JP6767347B2 (ja) | 2015-03-02 | 2017-11-21 | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546893A Active JP6336684B2 (ja) | 2015-03-02 | 2016-03-01 | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9572837B2 (ja) |
| EP (2) | EP3549612A1 (ja) |
| JP (2) | JP6336684B2 (ja) |
| KR (1) | KR102133857B1 (ja) |
| CN (2) | CN107073138B (ja) |
| AU (1) | AU2016228080B2 (ja) |
| BR (1) | BR112017018770A2 (ja) |
| CA (1) | CA2976684C (ja) |
| RU (1) | RU2688692C2 (ja) |
| SG (1) | SG11201706947TA (ja) |
| WO (1) | WO2016138846A1 (ja) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170109052A (ko) * | 2015-02-06 | 2017-09-27 | 내셔널 유니버시티 오브 싱가포르 | 치료적 면역 세포의 효능의 향상 방법 |
| JP6336684B2 (ja) | 2015-03-02 | 2018-06-06 | イノベイティブ セルラー セラピューティクス シーオー．，エルティディ．Ｉｎｎｏｖａｔｉｖｅ Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．，Ｌｔｄ． | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
| AU2016264323B2 (en) | 2015-05-18 | 2021-02-18 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| EP3344284A1 (en) | 2015-09-04 | 2018-07-11 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| WO2017100428A1 (en) | 2015-12-09 | 2017-06-15 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
| ES2962588T3 (es) * | 2016-03-23 | 2024-03-20 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Proteínas de fusión de PD-1 y 4-1BB |
| US10654934B2 (en) | 2016-04-01 | 2020-05-19 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| EP3436059B1 (en) | 2016-04-01 | 2022-01-12 | Innovative Cellular Therapeutics Holdings, Ltd. | Use of chimeric antigen receptor modified cells to treat cancer |
| AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| US11738048B2 (en) | 2016-08-30 | 2023-08-29 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| WO2018064921A1 (en) * | 2016-10-06 | 2018-04-12 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| ES2875959T3 (es) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| KR20190085528A (ko) | 2016-11-22 | 2019-07-18 | 싱가포르국립대학교 | T 세포 악성종양의 면역요법을 위한 키메라 항원 수용체 및 cd7 발현의 차단 |
| CN108148862B (zh) * | 2016-12-05 | 2019-03-08 | 上海优卡迪生物医药科技有限公司 | 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用 |
| WO2018104473A1 (en) | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| AU2018256436A1 (en) | 2017-04-19 | 2019-11-07 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| KR20200035304A (ko) | 2017-08-10 | 2020-04-02 | 싱가포르국립대학교 | T 세포 수용체-결핍 키메라 항원 수용체 t-세포 및 이의 사용 방법 |
| CN111433354A (zh) * | 2017-09-26 | 2020-07-17 | 朗沃德大学 | 作为免疫疗法的pd1特异性嵌合抗原受体 |
| CN109836493A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向cd19的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| US10561686B2 (en) * | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| AU2019209428A1 (en) | 2018-01-22 | 2020-07-30 | Endocyte, Inc. | Methods of use for CAR T cells |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US20220348682A1 (en) | 2018-08-30 | 2022-11-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| US20210379149A1 (en) * | 2018-10-25 | 2021-12-09 | Innovative Cellular Therapeutics Holdings, Ltd. | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| WO2020116686A1 (ko) * | 2018-12-06 | 2020-06-11 | 고려대학교 산학협력단 | 인간 항-antxr 키메라 항원 수용체 및 이의 용도 |
| CN109971842A (zh) * | 2019-02-15 | 2019-07-05 | 成都美杰赛尔生物科技有限公司 | 一种检测CRISPR-Cas9脱靶效应的方法 |
| US20220088074A1 (en) * | 2019-02-21 | 2022-03-24 | Regents Of The University Of Minnesota | Genetically modified gamma delta t cells and methods of making and using |
| US11739136B2 (en) * | 2019-03-18 | 2023-08-29 | Innovative Cellular Therapeutics Holdings, Ltd. | Inducible dominant negative PD-1 and uses in adoptive cell therapy |
| CN109868263A (zh) * | 2019-03-29 | 2019-06-11 | 深圳精准医疗科技有限公司 | 重组单纯疱疹病毒及其制备方法和应用、重组载体的构建方法及其应用 |
| EP3969470A4 (en) * | 2019-05-16 | 2023-06-28 | Memorial Sloan Kettering Cancer Center | Mesothelin cars and uses thereof |
| CN110423767A (zh) * | 2019-07-12 | 2019-11-08 | 华东师范大学 | 表达可溶性pd-1的嵌合抗原受体car基因及应用 |
| CN110592140A (zh) * | 2019-09-30 | 2019-12-20 | 王清路 | Pd-1基因缺陷型pd-1-cart细胞制剂的制法 |
| KR102647888B1 (ko) * | 2019-11-26 | 2024-03-13 | 난트퀘스트, 인크. | 일차 nk car 구축물 및 방법(primary nk car constructs and methods) |
| JP7198302B2 (ja) * | 2021-03-08 | 2022-12-28 | 一般財団法人 化学物質評価研究機構 | Ｐｄ－１を介した免疫チェックポイント阻害剤の生物活性試験法 |
| US20230227779A1 (en) | 2022-01-19 | 2023-07-20 | Innovative Cellular Therapeutics Holdings, Ltd. | Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor Microenvironment |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| AU2002362273A1 (en) * | 2001-09-07 | 2003-03-24 | Everygene Ab | Polymorphisms of pd-1 |
| AP2013006918A0 (en) | 2010-12-09 | 2013-06-30 | Univ Pennsylvania | Use of chimeric antigen receptormodified T-cells to treat cancer |
| EP3915588A1 (en) | 2011-07-29 | 2021-12-01 | The Trustees of the University of Pennsylvania | Switch costimulatory receptors |
| US9688740B2 (en) * | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
| ES2774160T3 (es) * | 2012-02-13 | 2020-07-17 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos |
| WO2013176915A1 (en) * | 2012-05-25 | 2013-11-28 | Roman Galetto | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| WO2014059173A2 (en) * | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| KR102593475B1 (ko) * | 2013-02-26 | 2023-10-26 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| US9745368B2 (en) * | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CN105431449B (zh) | 2013-04-05 | 2021-08-24 | 港大科桥有限公司 | 新的pd1同种型及其用于加强免疫应答的用途 |
| KR102164455B1 (ko) | 2013-05-08 | 2020-10-13 | 삼성전자주식회사 | 콘텐트 제공 방법, 콘텐트 제공 장치 및 그 콘텐트 제공 시스템 |
| EP4119662A1 (en) * | 2013-05-10 | 2023-01-18 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| WO2015142661A1 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| PL3177640T3 (pl) * | 2014-08-08 | 2020-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania |
| JP6336684B2 (ja) | 2015-03-02 | 2018-06-06 | イノベイティブ セルラー セラピューティクス シーオー．，エルティディ．Ｉｎｎｏｖａｔｉｖｅ Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．，Ｌｔｄ． | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
| US10493139B2 (en) | 2015-07-24 | 2019-12-03 | Innovative Cellular Therapeutics CO., LTD. | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor |
| EP3344284A1 (en) | 2015-09-04 | 2018-07-11 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| US11207393B2 (en) | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
| WO2017100428A1 (en) | 2015-12-09 | 2017-06-15 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
| EP3586852B8 (en) | 2018-01-11 | 2021-04-28 | Innovative Cellular Therapeutics Inc. | Modified cell expansion and uses thereof |
| US20210379149A1 (en) | 2018-10-25 | 2021-12-09 | Innovative Cellular Therapeutics Holdings, Ltd. | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy |
-
2016
- 2016-03-01 JP JP2017546893A patent/JP6336684B2/ja active Active
- 2016-03-01 CN CN201680002926.1A patent/CN107073138B/zh active Active
- 2016-03-01 BR BR112017018770-1A patent/BR112017018770A2/pt active Search and Examination
- 2016-03-01 RU RU2017130985A patent/RU2688692C2/ru active
- 2016-03-01 AU AU2016228080A patent/AU2016228080B2/en active Active
- 2016-03-01 EP EP19172425.1A patent/EP3549612A1/en active Pending
- 2016-03-01 CA CA2976684A patent/CA2976684C/en active Active
- 2016-03-01 KR KR1020177027722A patent/KR102133857B1/ko active IP Right Grant
- 2016-03-01 WO PCT/CN2016/075061 patent/WO2016138846A1/en active Application Filing
- 2016-03-01 SG SG11201706947TA patent/SG11201706947TA/en unknown
- 2016-03-01 EP EP16717825.0A patent/EP3089761B1/en active Active
- 2016-03-01 CN CN201810281004.XA patent/CN108410892B/zh active Active
- 2016-04-07 US US15/093,643 patent/US9572837B2/en active Active
- 2016-12-08 US US15/373,012 patent/US10619136B2/en active Active
-
2017
- 2017-11-21 JP JP2017223489A patent/JP6767347B2/ja active Active
-
2019
- 2019-05-06 US US16/404,349 patent/US10865382B2/en active Active
-
2020
- 2020-11-23 US US17/101,780 patent/US11932873B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018064568A5 (ja) | ||
| RU2017130985A (ru) | Фармацевтическая композиция и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека | |
| JP2017518037A5 (ja) | ||
| JP2018508219A5 (ja) | ||
| JP2016532693A5 (ja) | ||
| JP2020114264A5 (ja) | ||
| JP2016502512A5 (ja) | ||
| JP2015212284A5 (ja) | ||
| JP2017522862A5 (ja) | ||
| JP2018518990A5 (ja) | ||
| WO2018187613A3 (en) | Anti-icos agonist antibodies and uses thereof | |
| JP2014534207A5 (ja) | ||
| JP2018029594A5 (ja) | ||
| PH12016502011A1 (en) | Transgene genetic tags and methods of use | |
| EP4282878A3 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| WO2015104406A3 (en) | Multi-specific polypeptide useful for localized tumor immunomodulation | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| JP2017537627A5 (ja) | ||
| JP2016534717A5 (ja) | ||
| IL292650B1 (en) | IL13RA2-targeted chimeric antigen receptor T cells | |
| JP2018528786A5 (ja) | ||
| HRP20231382T1 (hr) | Pd-l1 varijanta imunomodulacijskih proteina i njihova upotreba | |
| JP2009201525A5 (ja) | ||
| JP2017527272A5 (ja) | ||
| JP2019508444A5 (ja) |